FDA Issues Draft Guidance to Reduce Animal Testing for Cancer Drugs

The FDA released draft guidance aimed at cutting unnecessary animal testing in nonclinical safety assessments for certain cancer medications. The initiative seeks to streamline drug development processes while maintaining safety standards.